Showing results (2261-2270 of 2,611) with videos related to

Sort By:
Pageof 262
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|November 29, 2021
A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant responseGiuseppe Fanelli, Katharina Domschke, Alessandra Minelli, et al.
American Heart Journal|May 21, 2018
International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: Rationale and design, David J Maron, Judith S Hochman, et al.
Genome|January 5, 2006
Molecular characterization and mapping of ALMT1, the aluminium-tolerance gene of bread wheat (Triticum aestivum L.)Harsh Raman, Kerong Zhang, Mehmet Cakir, et al.
The American Journal of Cardiology|July 7, 2009
Impact of optimal medical therapy with or without percutaneous coronary intervention on long-term cardiovascular end points in patients with stable coronary artery disease (from the COURAGE Trial)William E Boden, Robert A O'Rourke, Koon K Teo, et al.
The American Journal of Cardiology|October 6, 2009
Impact of an initial strategy of medical therapy without percutaneous coronary intervention in high-risk patients from the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trialDavid J Maron, John A Spertus, G B John Mancini, et al.
Circulation. Cardiovascular Interventions|November 3, 2011
Angiographic disease progression and residual risk of cardiovascular events while on optimal medical therapy: observations from the COURAGE TrialG B John Mancini, Pamela M Hartigan, Eric R Bates, et al.
The British Journal of Surgery|December 16, 2025
Genomic and clinical parallels between US and Japanese gastric cancers: a propensity score-matched cohort studyMasaya Nakauchi, Colin Court, Henry S Walch, et al.
American Heart Journal|September 11, 2013
Prognostic importance of coronary anatomy and left ventricular ejection fraction despite optimal therapy: assessment of residual risk in the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation TrialG B John Mancini, Pamela M Hartigan, Eric R Bates, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|October 21, 2024
Outcomes with revascularisation versus conservative management of participants with 3-vessel coronary artery disease in the ISCHEMIA trialSripal Bangalore, Grace Rhodes, David J Maron, et al.
Lancet Regional Health. Americas|May 29, 2024
Effectiveness of mass dengue vaccination with CYD-TDV (Dengvaxia®) in the state of Paraná, Brazil: integrating case-cohort and case-control designsFredi Alexander Diaz-Quijano, Denise Siqueira de Carvalho, Sonia Mara Raboni, et al.
Pageof 262